Are Shares Criminally Undervalued At GlaxoSmithKline Plc, Aberdeen Asset Management Plc & International Consolidated Airlines Group SA?

Are there bargains to be found at GlaxoSmithKline Plc (LON: GSK), Aberdeen Asset Management Plc (LON: ADN) and International Consolidated Airlines Group SA (LON: IAG)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Low valuations combined with dividends have always been the value-hunter’s greatest dream. With price/earnings ratios below 11 and regular dividends, is the market undervaluing GlaxoSmithKline (LSE: GSK), Aberdeen Asset Management (LSE: ADN) and International Consolidated Airlines Group (LSE: IAG)?

Dividend cut ahead?

Emerging markets-focused asset manager Aberdeen has suffered 11 straight quarters of withdrawals due to poorly performing funds and the meltdown in developing economies. Plummeting share prices mean the company now offers an 8% yield and a P/E ratio of 11. While investors may find these numbers hard to resist, there could be worse to come for shares.

Earnings are expected to collapse by more than a third this year, which will barely cover dividend payouts. If major institutional clients continue fleeing Aberdeen’s funds, a dividend cut becomes very likely. And with any turnaround in market sentiment towards developing economies out of sight, I’m happy to sit on the sidelines and wait for a turnaround before plonking my money into shares.

Should you invest £1,000 in BAE Systems right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BAE Systems made the list?

See the 6 stocks

Safe play

Pharmaceuticals giant GSK certainly appears to fit the bill of a bargain share, trading at a P/E of eight and offering a 5.8% yielding dividend. Unfortunately, this eye-catching valuation is due to one-off profits received from an asset swap deal with Novartis. GSK’s 2016 forecast P/E is a more reasonable 16 times earnings.

Despite this higher valuation, GSK could still be an attractive opportunity for investors. Management has shifted focus from being a pureplay drugs manufacturer to having a more diversified portfolio of drugs, consumer healthcare goods, and vaccines. The healthcare segment and vaccines now account for 26% and 16% of revenue, respectively, providing less lumpy revenue streams year-after-year.

The traditional pharmaceuticals division will still be there to provide growth for GSK, with the most promising option being a series of new HIV treatments. HIV treatments already contribute 29% of profits, and this number is expected to continue growing as GSK gains market share. Earnings are expected to grow 12% next year, and increase from there. A once-again-safely-covered dividend and growth potential make me think that GSK could be a relatively safe play for income-hungry investors going forward.

Proving us all wrong

The parent of British Airways and Iberia, IAG, has been proving wrong the long-held sentiment that airline shares were good for little more than losing your money. Share prices are up 145% over the past five years and yet the shares trade at a mere 6.7 times forward earnings. This low valuation and a 3.5% dividend pencilled-in for 2016 will surely have value investors eagerly adding the shares to their watch lists.

While plummeting oil prices have played their part, increased efficiency at both BA and Iberia have been the largest drivers of growth. In fact, fuel prices for the company fell only 6.3% last year while profits rose a full 51%. If the company were only doing well thanks to historically low oil prices, I would be wary of the shares. However, with the company expanding astutely only on high-margin routes and buying up stakes in turnaround carriers such as Aer Lingus, IAG does have the potential to break the mould and be an airline that actually provides high shareholder returns.

AI Revolution Awaits: Uncover Top Stock Picks for Massive Potential Gains!

Buckle up because we're about to dive headfirst into the electrifying world of AI.

Imagine this: you make a single savvy investment in some cutting-edge technology, then kick back and watch as it revolutionises entire industries and potentially even lines your pockets.

If the mere thought of riding this AI wave excites you and the prospect of massive potential returns gets your pulse racing, then you’ve got to check out this Motley Fool Share Advisor report – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And here’s the kicker – we’re giving you an exclusive peek at ONE of these top AI stock picks, absolutely free! How’s that for a bit of brilliance?

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has recommended Aberdeen Asset Management and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

These 4 FTSE shares have crashed hard. Which do I like today?

These four FTSE 100 stocks have plunged in value over the last month. But after this latest market meltdown, which…

Read more »

Investing Articles

1 FTSE 250 stock that analysts are calling a ‘Strong Buy’

The FTSE 250 can be overlooked by investors, but analysts believe this stock in particular could be undervalued by as…

Read more »

Close up of a group of friends enjoying a movie in the cinema
Investing Articles

I asked ChatGPT to name 5 FTSE shares for the perfect SIPP. Here’s what it picked

Harvey Jones called on ChatGPT to help him decide which shares would be right to buy for a well-balanced SIPP.…

Read more »

Investing Articles

Should I load up on Rolls-Royce shares after the 17% drop?

Rolls-Royce shares have pulled back sharply in the FTSE 100 in recent weeks, leaving this Fool to wonder if he…

Read more »

Investing Articles

Is this the best S&P 500 stock to consider buying in these volatile times?

With bullion prices still rocketing, I think buying the S&P 500's only gold stock is worth serious consideration right now.

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Yielding 7.25% but with a P/E of 186x! What’s up with the BP share price?

Harvey Jones thought the BP share price was a brilliant bargain but it's only brought him a world of trouble.…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Down 26% with a 7% yield! Could this little-known FTSE 250 gem make a comeback?

Mark Hartley considers the long-term prospects of FTSE 250 recruiter Page Group. Weak results have sent the price tumbling but…

Read more »

Investing Articles

Analysts are calling Diageo shares a strong buy! Are they mad?

Analysts still have faith in Diageo shares, with 10 of them giving it the highest possible stock rating. Harvey Jones…

Read more »